कृपया अन्य खोज का प्रयास करें
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren’s Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Anne-Laure Autret-Cornet | - | 2016 | CFO, Administrative & Financial Director and Employee Shareholder Representative Director |
Wolf-Herve Fridman | - | 2013 | Chairman of the Scientific Board |
Sophie Brouard | 53 | 2016 | Director of External Affairs & Member of the Scientific Advisory Board |
Markus Goebel | 71 | 2024 | Independent director |
Didier Hoch | 68 | 2016 | Independent Chairman of the Board of Directors |
Myriam Merad | - | 2022 | Member of Scientific Advisory Board |
Maryvonne Hiance | 75 | 2016 | Vice Chairwoman |
Jennifer Wargo | - | 2022 | Member of Scientific Advisory Board |
Eric Leire | - | 2023 | Independent Director |
Charles N. Serhan | - | 2022 | Member of Scientific Advisory Board |
Marc Dechamps | - | 2024 | Independent Director |
Bernard Malissen | - | 2022 | Member of Scientific Advisory Board |
Cécile Nguyen-Cluzel | 52 | 2024 | Independent Director |
Martine Ortin George | 75 | 2024 | Independent director |
Nicolas Poirier | 42 | 2016 | General Director, CEO, Scientific Director & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है